Founded in 2014 as a spin-off of the French Blood Bank (EFS), PDC line Pharma is a Belgian-French clinical-stage biotech company that develops an innovative class of active immunotherapies for cancers based on a GMP-grade allogeneic therapeutic cell line of Plasmacytoid Dendritic Cells (PDC line). PDC line is much more potent than conventional dendritic cell-based vaccines in priming and boosting antitumor antigen-specific cytotoxic T-cells, including those specific for neoantigens, and is synergistic with checkpoint inhibitors. The technology can potentially be applied to any cancer. Following a first-in-human phase I feasibility study in melanoma, PDC line Pharma focuses on the development of PDC lung01, a candidate for Non-Small-Cell Lung Cancer (NSCLC) currently in phase I/II trials, and PDC with neoantigens in preclinical development. The company has a staff of 42, with an experienced management team. It has raised close to €56M in equity and non-dilutive funding.